| MAN1B1 |
Homo sapiens |
|
MAN1B1 is differentially expressed in 66 experiments [75 up/75 dn]: 22 organism parts: cerebellum [1 up/0 dn], white blood cells [0 up/1 dn], ...; 19 disease states: normal [2 up/5 dn], acute promyelocytic leukemia [1 up/0 dn], ...; 16 cell types, 21 cell lines, 22 compound treatments and 17 other conditions. |
| DKFZp434I213, MAN1B1, RP11-350O14.2-005, UNQ747/PRO1477 |
|
Man1b1 (Mus musculus)
MNS1 (Saccharomyces cerevisiae)
(Compare orthologs)
|
|
|
| Glycoside hydrolase, family 47 |
|
|
| endoplasmic reticulum, integral to membrane, mannosyl-oligosaccharide 1,2-alpha-mannosidase activity, membrane fraction, protein amino acid N-linked glycosylation |
|
|
|
Q59G33
Q5VSF2
Q8N2P4
Q9UKM7
Q9UFZ8
|
|
|
|
ENSG00000177239
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Normal
|
Disease state |
|
|
Stromal cell
|
Cell type |
|
|
FLAP
|
Compound treatment |
|
|
HNRPA2B
|
Compound treatment |
|
|
MK886
|
Compound treatment |
|
|
PC3
|
Cell line |
|
|
Epithelial cell
|
Cell type |
|
|
Placebo
|
Compound treatment |
|
|
MDA-MB-231
|
Cell line |
|
|
Cerebellum
|
Organism part |
|
|
SW480
|
Cell line |
|
|
SW620
|
Cell line |
|
|
HL-60
|
Cell line |
|
|
None
|
Compound treatment |
|
|
MCF7
|
Cell line |
|
|
Glucocorticoid resistant
|
Phenotype |
|
|
Pretreatment primary sample
|
Clinical info |
|
|
White blood cells
|
Organism part |
|
|
Glucocorticoid sensitive
|
Phenotype |
|
|
Tumor
|
Organism part |
|
|
BT474
|
Cell line |
|
|
SsMCF7
|
Cell line |
|
|
Rapamycin
|
Compound treatment |
|
|
Atrial mycocardium
|
Organism part |
|
|
Ventricular myocardium
|
Organism part |
|
|
Lymphatic endothelial cell
|
Cell type |
|
|
HaCaT
|
Cell line |
|
|
Control for heregulin
|
Compound treatment |
|
|
Acute promyelocytic leukemia
|
Disease state |
|
|
U937
|
Cell line |
|
|
HPL1
|
Cell line |
|
|
Kaposi's sarcoma-associated he...
|
Infection |
|
|
Heregulin
|
Compound treatment |
|
|
Dimethyl sulfoxide
|
Compound treatment |
|
|
Epidermal growth factor
|
Compound treatment |
|
|
Breast carcinoma
|
Disease state |
|
|
N/a
|
Test result |
|
|
Caudate nucleus
|
Organism part |
|
|
Malignant melanoma
|
Disease state |
|
|
Serum starvation + thymidine b...
|
Growth condition |
|
|
Invasive ductal carcinoma
|
Histology |
|
|
Frontal cortex, superior motor...
|
Organism part |
|
|
Not applicable
|
Histology |
|
|
0 cm away from the tumor bound...
|
Observation |
|
|
MCF10A
|
Cell line |
|
|
Endothelial cell
|
Cell type |
|
|
Frontal cortex, primary motor ...
|
Organism part |
|
|
MDA468
|
Cell line |
|
|
Trigeminal ganglion
|
Organism part |
|
|
Uterus corpus
|
Organism part |
|
|
Beas2B
|
Cell line |
|
|
M1 macrophage
|
Cell type |
|
|
Whole blood
|
Organism part |
|
|
Duchenne muscular dystrophy
|
Disease state |
|
|
Interferon-gamma + lipopolysac...
|
Compound treatment |
|
|
Geriatric
|
Developmental stage |
|
|
Pediatric
|
Developmental stage |
|
|
Benign prostatic hyperplasia
|
Disease state |
|
|
Prostate carcinoma
|
Disease state |
|
|
Primary cells
|
Cell line |
|
|
Primary gastric tumor
|
Organism part |
|
|
Adipose-derived stem cell
|
Cell type |
|
|
Grade IV
|
Tumor grading |
|
|
Glioblastoma
|
Disease state |
|
|
Training set
|
Population |
|
|
Test set
|
Population |
|
|
IL-4
|
Compound treatment |
|
|
Superior cervical ganglion
|
Organism part |
|
|
Johnsen score count 10: full s...
|
Histology |
|
|
Baseline uninfected
|
Disease state |
|
|
Epilepsy
|
Disease state |
|
|
M2 macrophage
|
Cell type |
|
|
Viral load low
|
Clinical history |
|
|
Macrophage
|
Cell type |
|
|
Media only
|
Growth condition |
|
|
Ethanol
|
Vehicle |
|
|
10 ng/ml LPS in media
|
Growth condition |
|
|
Secretory cell
|
Cell type |
|
|
Glutamine
|
Compound treatment |
|
|
DMSO
|
Vehicle |
|
|
Organism_part
|
Material type |
|
|
Cell
|
Material type |
|
|
Kaposi's sarcoma
|
Disease state |
|
|
Bacterial endotoxin
|
Compound treatment |
|
|
Control
|
Compound treatment |
|
|
Multiple myeloma
|
Disease state |
|
|
Monocyte
|
Cell type |
|
|
Trichostatin A
|
Compound treatment |
|
|
Symptomatic
|
Disease staging |
|
|
M-CSF
|
Compound treatment |
|
|
Salivary gland
|
Organism part |
|
|
Cingulate cortex
|
Organism part |
|
|
HTERT transfection
|
Gene modification |
|
|
Mannitol
|
Compound treatment |
|
|
HTERT/HPVE6/HPVE7/SV40t transf...
|
Gene modification |
|
|
Dermatomyositis
|
Disease state |
|
|
BL41K3
|
Cell line |
|
|
BJABK3
|
Cell line |
|
|
In vitro neutrophil
|
Cell type |
|
|
HTERT/HPVE6/HPVE7/SV40t/hRas t...
|
Gene modification |
|
|
Johnsen score count 5: no sper...
|
Histology |
|
|
Johnsen score count 2: Sertoli...
|
Histology |
|
|
HeLa
|
Cell line |
|
|
Ciliary ganglion
|
Organism part |
|
|
CD71+ early erythroid
|
Cell type |
|
|
Baseline sevoflurane
|
Compound treatment |
|
|
Selenium
|
Compound treatment |
|
|
HMEC184
|
Cell line |
|
|
Atrioventricular node
|
Organism part |
|
|
Wild_type
|
Genotype |
|
|
Testis
|
Organism part |
|
|
R-(-)-apomorphine HCl
|
Compound treatment |
|
|
Beta cell islets
|
Organism part |
|
|
Plasma cell
|
Cell type |
|
|
B lymphocyte
|
Cell type |
|
|
Skin
|
Organism part |
|
|
Chronic myelogenous leukemia
|
Disease state |
|
|
T47D
|
Cell line |
|
|
Colorectal adenocarcinoma
|
Disease state |
|
|
Unsynchronized
|
Growth condition |
|
|
Metastatic
|
Disease staging |
|
|
STK3 overexpression
|
Genotype |
|
|
Control
|
RNAi |
|
|
SIM2s
|
RNAi |
|
|
Acute malaria, natural infecti...
|
Disease state |
|
|
Ulcerative colitis
|
Disease state |
|
|
5-aza-2'-deoxycytidine + trich...
|
Compound treatment |
|
|
White blood cell
|
Cell type |
|
|
Platelet
|
Cell type |
|
|
Aggregatibacter actinomycetemc...
|
Infection |
|
|
Huntington's disease
|
Disease state |
|
|
Adrenal cortex
|
Organism part |
|
|
Ischemic cardiomyopathy
|
Disease state |
|
|
Fetal lung
|
Organism part |
|
|
Met5A
|
Cell line |
|
|
|
|
|
Processing time: 0.26 secs.